drugset / Trial / NCT04576871
Re-treatment 225Ac-J591 for mCRPC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if re-treatment with 225Ac-J591 can be given without severe side effects.
Timeline
- Start
- 2020-10-29
- Primary completion
- 2023-08-31
- Completion
- 2024-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 225Ac-J591 | Monoclonal antibody | 50 ug/kg | — |
| Subject | 225Ac-J591 | Monoclonal antibody | 65 ug/kg | — |